Temat: "Drug Substitution" - OpacWWW

Skocz do pozycji: 41.

Tytuł:: Same but different? A thematic analysis on adalimumab biosimilar switching among patients with juvenile idiopathic arthritis.
Autorzy:: Renton WD; Bristol Royal Hospital for Children, University Hospitals Bristol NHS Foundation Trust, Bristol, UK.
Leveret H; Bristol Royal Hospital for Children, University Hospitals Bristol NHS Foundation Trust, Bristol, UK.
Guly C; Bristol Eye Hospital, University Hospitals Bristol NHS Foundation Trust, Bristol, UK.
Smee H; Bristol Royal Hospital for Children, University Hospitals Bristol NHS Foundation Trust, Bristol, UK.
Leveret J; Bristol Royal Hospital for Children, University Hospitals Bristol NHS Foundation Trust, Bristol, UK.
Ramanan AV; Bristol Royal Hospital for Children, University Hospitals Bristol NHS Foundation Trust, Bristol, UK. .; Translational Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK. .; Pokaż więcej
Źródło:: Pediatric rheumatology online journal [Pediatr Rheumatol Online J] 2019 Oct 04; Vol. 17 (1), pp. 67. Date of Electronic Publication: 2019 Oct 04.
Typ publikacji:: Journal Article
MeSH Terms:: Drug Substitution*
Adalimumab/*therapeutic use
Antirheumatic Agents/*therapeutic use
Arthritis, Juvenile/*drug therapy
Biosimilar Pharmaceuticals/*therapeutic use
Adolescent ; Child ; Female ; Humans ; Interviews as Topic ; Male ; Treatment Failure

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 42.

Tytuł:: Efficacy and safety of the switch of Triumeq : data at 48 weeks.
Autorzy:: Pérez-Stachowski J; a Department of Internal Medicine, Hospital Costa del Sol , Marbella , Spain.
Tortajada B; b Department of Pharmacy, Hospital Costa del Sol , Marbella , Spain.
Del Arco A; a Department of Internal Medicine, Hospital Costa del Sol , Marbella , Spain.
Márquez E; b Department of Pharmacy, Hospital Costa del Sol , Marbella , Spain.
De la Torre J; a Department of Internal Medicine, Hospital Costa del Sol , Marbella , Spain.
Nieto M; b Department of Pharmacy, Hospital Costa del Sol , Marbella , Spain.
García de Lomas JM; a Department of Internal Medicine, Hospital Costa del Sol , Marbella , Spain.
Prada JL; a Department of Internal Medicine, Hospital Costa del Sol , Marbella , Spain.
García-Alegría J; a Department of Internal Medicine, Hospital Costa del Sol , Marbella , Spain.
Olalla J; a Department of Internal Medicine, Hospital Costa del Sol , Marbella , Spain.; Pokaż więcej
Źródło:: Infectious diseases (London, England) [Infect Dis (Lond)] 2019 Sep; Vol. 51 (9), pp. 691-693. Date of Electronic Publication: 2019 Jul 05.
Typ publikacji:: Journal Article
MeSH Terms:: Drug Substitution*
Anti-HIV Agents/*therapeutic use
Dideoxynucleosides/*therapeutic use
Drugs, Generic/*therapeutic use
HIV Infections/*drug therapy
Heterocyclic Compounds, 3-Ring/*therapeutic use
Lamivudine/*therapeutic use
Drug Combinations ; Female ; Humans ; Male ; Middle Aged ; Retrospective Studies ; Spain

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 43.

Tytuł:: Darunavir/cobicistat/emtricitabine/tenofovir alafenamide in treatment-experienced, virologically suppressed patients with HIV-1: subgroup analyses of the phase 3 EMERALD study.
Autorzy:: Huhn GD; The Ruth M. Rothstein CORE Center, 2020 W Harrison Street, Chicago, IL, 60612, USA. .
Eron JJ; University of North Carolina School of Medicine, 321 S Columbia St., Chapel Hill, NC, 27516, USA.
Girard PM; Hôpital St Antoine, Assistance Publique-Hôpitaux de Paris and Sorbonne University, 184 rue du Faubourg Saint-Antoine, 75012, Paris, France.
Orkin C; Queen Mary University of London, Mile End Rd, Bethnal Green, London, E1 4NS, UK.
Molina JM; University of Paris Diderot, St-Louis Hospital, 12 Rue de la Grange aux Belles, 75010, Paris, France.
DeJesus E; Orlando Immunology Center, 1707 North Mills Avenue, Orlando, FL, 32803, USA.
Petrovic R; Janssen Research & Development, Turnhoutseweg 30, 2340, Beerse, Belgium.
Luo D; Janssen Research & Development, LLC, 1125 Trenton-Harbourton Road, Titusville, NJ, 08560, USA.
Van Landuyt E; Janssen Research & Development, Turnhoutseweg 30, 2340, Beerse, Belgium.
Lathouwers E; Janssen Research & Development, Turnhoutseweg 30, 2340, Beerse, Belgium.
Nettles RE; Janssen Scientific Affairs, LLC, 1125 Trenton-Harbourton Road, Titusville, NJ, 08560, USA.
Brown K; Janssen Research & Development, LLC, 1125 Trenton-Harbourton Road, Titusville, NJ, 08560, USA.
Wong EY; Janssen Scientific Affairs, LLC, 1125 Trenton-Harbourton Road, Titusville, NJ, 08560, USA.; Pokaż więcej
Źródło:: AIDS research and therapy [AIDS Res Ther] 2019 Aug 29; Vol. 16 (1), pp. 23. Date of Electronic Publication: 2019 Aug 29.
Typ publikacji:: Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
MeSH Terms:: Drug Substitution*
Anti-HIV Agents/*therapeutic use
HIV Infections/*drug therapy
Viral Load/*drug effects
Adenine/analogs & derivatives ; Adenine/therapeutic use ; Adult ; Aged ; Alanine ; Antiretroviral Therapy, Highly Active ; Cobicistat/therapeutic use ; Darunavir/therapeutic use ; Drug Combinations ; Emtricitabine/therapeutic use ; Female ; HIV-1/drug effects ; Humans ; Male ; Middle Aged ; Protease Inhibitors/therapeutic use ; Sustained Virologic Response ; Tablets ; Tenofovir/therapeutic use ; Young Adult

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 44.

Tytuł:: Beta-blocker choice and exchangeability in patients with heart failure and chronic obstructive pulmonary disease: an Italian register-based cohort study.
Autorzy:: Sessa M; Department of Drug Design and Pharmacology, University of Copenhagen, Jagtvej 160, 2100, København Ø, Denmark. .; Campania Pharmacovigilance and Pharmacoepidemiology Regional Centre, Department of Experimental Medicine, University of Campania 'L. Vanvitelli', Via Santa Maria di Costantinopoli 16, 80138, Naples, Italy. .
Mascolo A; Campania Pharmacovigilance and Pharmacoepidemiology Regional Centre, Department of Experimental Medicine, University of Campania 'L. Vanvitelli', Via Santa Maria di Costantinopoli 16, 80138, Naples, Italy.
Rasmussen DB; Respiratory Research Unit Zealand, Department of Respiratory Medicine, Naestved Hospital, Ringstedgade 61, 4700, Næstved, Denmark.; Department of Cardiology, Herlev and Gentofte University Hospital, Gentofte Hospitalsvej 1, 2900, Hellerup, Denmark.
Kragholm K; Unit of Epidemiology and Biostatistics, Aalborg University Hospital, Hobrovej 18-22, 9100, Aalborg, Denmark.
Jensen MT; Heart Centre, Copenhagen University Hospital Rigshospitalet, Blegdamsvej 9, 2100, København, Denmark.
Sportiello L; Campania Pharmacovigilance and Pharmacoepidemiology Regional Centre, Department of Experimental Medicine, University of Campania 'L. Vanvitelli', Via Santa Maria di Costantinopoli 16, 80138, Naples, Italy.
Rafaniello C; Campania Pharmacovigilance and Pharmacoepidemiology Regional Centre, Department of Experimental Medicine, University of Campania 'L. Vanvitelli', Via Santa Maria di Costantinopoli 16, 80138, Naples, Italy.
Tari GM; Caserta Local Health Unit, Via Unità Italiana 28, 81100, Caserta, Italy.
Pagliaro C; Caserta Local Health Unit, Via Unità Italiana 28, 81100, Caserta, Italy.
Andersen M; Department of Drug Design and Pharmacology, University of Copenhagen, Jagtvej 160, 2100, København Ø, Denmark.
Rossi F; Campania Pharmacovigilance and Pharmacoepidemiology Regional Centre, Department of Experimental Medicine, University of Campania 'L. Vanvitelli', Via Santa Maria di Costantinopoli 16, 80138, Naples, Italy.
Capuano A; Campania Pharmacovigilance and Pharmacoepidemiology Regional Centre, Department of Experimental Medicine, University of Campania 'L. Vanvitelli', Via Santa Maria di Costantinopoli 16, 80138, Naples, Italy.; Pokaż więcej
Źródło:: Scientific reports [Sci Rep] 2019 Aug 07; Vol. 9 (1), pp. 11465. Date of Electronic Publication: 2019 Aug 07.
Typ publikacji:: Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:: Adrenergic beta-Antagonists/*therapeutic use
Drug Substitution/*statistics & numerical data
Drug Utilization/*statistics & numerical data
Heart Failure/*drug therapy
Pulmonary Disease, Chronic Obstructive/*drug therapy
Adrenergic beta-Antagonists/standards ; Aged ; Aged, 80 and over ; Atrioventricular Block/epidemiology ; Bisoprolol/standards ; Bisoprolol/therapeutic use ; Carvedilol/standards ; Carvedilol/therapeutic use ; Cerebrovascular Disorders/epidemiology ; Cohort Studies ; Comorbidity ; Drug Prescriptions/standards ; Drug Prescriptions/statistics & numerical data ; Drug Substitution/standards ; Drug Utilization/standards ; Female ; Heart Failure/complications ; Heart Failure/epidemiology ; Hospitalization/statistics & numerical data ; Humans ; Italy/epidemiology ; Male ; Metoprolol/standards ; Metoprolol/therapeutic use ; Nebivolol/standards ; Nebivolol/therapeutic use ; Practice Guidelines as Topic ; Pulmonary Disease, Chronic Obstructive/complications ; Pulmonary Disease, Chronic Obstructive/epidemiology ; Registries/statistics & numerical data ; Renal Insufficiency, Chronic/epidemiology ; Retrospective Studies ; Thrombosis/epidemiology

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 45.

Tytuł:: Safety and Tolerability of Initiating Maximum-Dose Sacubitril-Valsartan in Patients on Target Dose Renin-Angiotensin System Inhibitors.
Autorzy:: Norberg H; Department of Public Health and Clinical Medicine, Umeå University, 901 87 Umeå, Sweden.; Department of Pharmacology and Clinical Neuroscience, Umeå University, 901 87 Umeå, Sweden.
Bergdahl E; Department of Public Health and Clinical Medicine, Umeå University, 901 87 Umeå, Sweden.
Lindmark K; Department of Public Health and Clinical Medicine, Umeå University, 901 87 Umeå, Sweden.; Pokaż więcej
Źródło:: Cardiovascular therapeutics [Cardiovasc Ther] 2019 Aug 01; Vol. 2019, pp. 6745074. Date of Electronic Publication: 2019 Aug 01 (Print Publication: 2019).
Typ publikacji:: Journal Article
MeSH Terms:: Drug Substitution*
Aminobutyrates/*administration & dosage
Angiotensin Receptor Antagonists/*administration & dosage
Angiotensin-Converting Enzyme Inhibitors/*administration & dosage
Heart Failure/*drug therapy
Renin-Angiotensin System/*drug effects
Tetrazoles/*administration & dosage
Aged ; Aged, 80 and over ; Aminobutyrates/adverse effects ; Angiotensin Receptor Antagonists/adverse effects ; Angiotensin-Converting Enzyme Inhibitors/adverse effects ; Biphenyl Compounds ; Drug Combinations ; Female ; Heart Failure/diagnosis ; Heart Failure/physiopathology ; Humans ; Male ; Maximum Tolerated Dose ; Middle Aged ; Patient Safety ; Prospective Studies ; Risk Assessment ; Tetrazoles/adverse effects ; Time Factors ; Treatment Outcome ; Valsartan

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 46.

Tytuł:: Efficacy and safety of adalimumab after failure of other anti-TNFα agents for plaque-type psoriasis: clinician behavior in real life clinical practice.
Autorzy:: Esposito M; a Department of Dermatology , University of Rome 'Tor Vergata' , Rome , Italy.
Prignano F; b Department of Dermatology , University of Florence , Firenze , Italy.
Rongioletti F; c Department of Medical Sciences and Public Health, Section of Dermatology , University of Cagliari , Cagliari , Italy.
Hansel K; d Department of Medicine, Section of Clinical, Allergological and Venereological Dermatology , University of Perugia , Perugia , Italy.
Bianchi L; d Department of Medicine, Section of Clinical, Allergological and Venereological Dermatology , University of Perugia , Perugia , Italy.
Pescitelli L; b Department of Dermatology , University of Florence , Firenze , Italy.
Lazzeri L; b Department of Dermatology , University of Florence , Firenze , Italy.
Ricceri F; b Department of Dermatology , University of Florence , Firenze , Italy.
Mugheddu C; c Department of Medical Sciences and Public Health, Section of Dermatology , University of Cagliari , Cagliari , Italy.
Bavetta M; a Department of Dermatology , University of Rome 'Tor Vergata' , Rome , Italy.
Zangrilli A; a Department of Dermatology , University of Rome 'Tor Vergata' , Rome , Italy.
Bianchi L; a Department of Dermatology , University of Rome 'Tor Vergata' , Rome , Italy.
Bini V; e Department of Medicine, Medicine, Endocrine and Metabolic Sciences Section , University of Perugia , Perugia , Italy.
Stingeni L; d Department of Medicine, Section of Clinical, Allergological and Venereological Dermatology , University of Perugia , Perugia , Italy.; Pokaż więcej
Źródło:: The Journal of dermatological treatment [J Dermatolog Treat] 2019 Aug; Vol. 30 (5), pp. 441-445. Date of Electronic Publication: 2018 Nov 06.
Typ publikacji:: Journal Article; Multicenter Study; Observational Study
MeSH Terms:: Drug Substitution*
Practice Patterns, Physicians'*
Adalimumab/*therapeutic use
Anti-Inflammatory Agents/*therapeutic use
Psoriasis/*drug therapy
Adult ; Aged ; Female ; Humans ; Male ; Middle Aged ; Retrospective Studies ; Treatment Outcome ; Tumor Necrosis Factor-alpha/antagonists & inhibitors

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 47.

Tytuł:: 'I saw it as a second chance': A qualitative exploration of experiences of treatment failure and regimen change among people living with HIV on second- and third-line antiretroviral therapy in Kenya, Malawi and Mozambique.
Autorzy:: Burns R; a Epicentre , Paris , France.
Borges J; b Médecins sans Frontières , Geneva , Switzerland.
Blasco P; c Médecins sans Frontières , Paris , France.
Vandenbulcke A; c Médecins sans Frontières , Paris , France.
Mukui I; d Ministry of Health, Nairobi , Kenya.
Magalasi D; c Médecins sans Frontières , Paris , France.
Molfino L; b Médecins sans Frontières , Geneva , Switzerland.
Manuel R; e Ministry of Health, Maputo , Mozambique.
Schramm B; a Epicentre , Paris , France.
Wringe A; f London School of Hygiene and Tropical Medicine , London , UK.; Pokaż więcej
Źródło:: Global public health [Glob Public Health] 2019 Aug; Vol. 14 (8), pp. 1112-1124. Date of Electronic Publication: 2019 Jan 11.
Typ publikacji:: Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:: Drug Substitution*
Anti-Retroviral Agents/*therapeutic use
HIV Infections/*drug therapy
Adult ; Cross-Sectional Studies ; Female ; Humans ; Interviews as Topic ; Kenya ; Malawi ; Male ; Medication Adherence ; Mozambique ; Qualitative Research ; Treatment Failure

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 48.

Tytuł:: Leveraging policy to reduce chronic opioid use by educating and empowering community dwelling adults: a study protocol for the TAPERING randomized controlled trial.
Autorzy:: Turner JP; Faculté de Pharmacie, Université de Montréal, Montréal, QC, Canada. .; Centre de Recherche de l'Institut Universitaire de Gériatrie de Montréal, Montréal, QC, Canada. .
Caetano P; Faculty of Health Sciences, University of Manitoba, Winnipeg, MB, Canada.; Provincial Drug Programs, Government of Manitoba, Winnipeg, MB, Canada.
Tannenbaum C; Centre de Recherche de l'Institut Universitaire de Gériatrie de Montréal, Montréal, QC, Canada.; Michel Saucier Endowed Chair in Pharmacology, Health and Aging, Facultés de Médecine et de Pharmacie, Université de Montréal, Montréal, QC, Canada.; Pokaż więcej
Źródło:: Trials [Trials] 2019 Jul 09; Vol. 20 (1), pp. 412. Date of Electronic Publication: 2019 Jul 09.
Typ publikacji:: Clinical Trial Protocol; Journal Article
MeSH Terms:: Deprescriptions*
Drug Substitution*
Pamphlets*
Analgesics, Opioid/*administration & dosage
Chronic Pain/*drug therapy
Opioid-Related Disorders/*prevention & control
Patient Education as Topic/*methods
Analgesics, Opioid/adverse effects ; Chronic Pain/diagnosis ; Chronic Pain/psychology ; Drug Administration Schedule ; Health Knowledge, Attitudes, Practice ; Health Policy ; Humans ; Manitoba ; Opioid-Related Disorders/diagnosis ; Opioid-Related Disorders/psychology ; Policy Making ; Postal Service ; Pragmatic Clinical Trials as Topic ; Prospective Studies ; Protective Factors ; Risk Assessment ; Risk Factors ; Time Factors

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 49.

Tytuł:: IL-17A Inhibitor Switching - Efficacy of Ixekizumab Following Secukinumab Failure. A Single-center Experience.
Autorzy:: Sherman S; Department of Dermatology, Rabin Medical Center - Beilinson Hospital, 4941492 Petach, Israel.
Solomon Cohen E
Amitay-Laish I
Hodak E
Pavlovsky L; Pokaż więcej
Źródło:: Acta dermato-venereologica [Acta Derm Venereol] 2019 Jul 01; Vol. 99 (9), pp. 769-773.
Typ publikacji:: Journal Article; Observational Study
MeSH Terms:: Drug Substitution*
Antibodies, Monoclonal, Humanized/*therapeutic use
Biological Products/*therapeutic use
Interleukin-17/*antagonists & inhibitors
Psoriasis/*drug therapy
Adult ; Aged ; Aged, 80 and over ; Antibodies, Monoclonal, Humanized/adverse effects ; Biological Products/adverse effects ; Female ; Humans ; Interleukin-17/immunology ; Male ; Middle Aged ; Psoriasis/diagnosis ; Psoriasis/immunology ; Retrospective Studies ; Severity of Illness Index ; Treatment Failure

Czasopismo naukowe

na półce

Pełny tekst Szczegóły

Skocz do pozycji: 50.

Tytuł:: Incidence, predictors, and prognosis of premature discontinuation or switch of prasugrel or ticagrelor: the ATLANTIS - SWITCH study.
Autorzy:: Winter MP; Department of Cardiology, Medical University of Vienna, Vienna, Austria.
von Lewinski D; Department of Cardiology, Medical University of Graz, Graz, Austria.
Wallner M; Department of Cardiology, Medical University of Graz, Graz, Austria.; Lewis Katz School of Medicine, Temple University, Cardiovascular Research Center, Philadelphia, PA, USA.
Prüller F; Clinical Institute of Medical and Chemical Laboratory Diagnostics, Medical University of Graz, Graz, Austria.
Kolesnik E; Department of Cardiology, Medical University of Graz, Graz, Austria.
Hengstenberg C; Department of Cardiology, Medical University of Vienna, Vienna, Austria.
Siller-Matula JM; Department of Cardiology, Medical University of Vienna, Vienna, Austria. .; Pokaż więcej
Źródło:: Scientific reports [Sci Rep] 2019 Jun 03; Vol. 9 (1), pp. 8194. Date of Electronic Publication: 2019 Jun 03.
Typ publikacji:: Journal Article; Multicenter Study; Observational Study
MeSH Terms:: Drug Substitution*
Anticoagulants/*therapeutic use
Myocardial Ischemia/*drug therapy
Prasugrel Hydrochloride/*therapeutic use
Ticagrelor/*therapeutic use
Acute Coronary Syndrome/drug therapy ; Aged ; Drug Administration Schedule ; Drug-Eluting Stents ; Female ; Hemorrhage/drug therapy ; Humans ; Incidence ; Kaplan-Meier Estimate ; Male ; Middle Aged ; Myocardial Ischemia/prevention & control ; Platelet Aggregation Inhibitors ; Prognosis ; Prospective Studies ; Purinergic P2Y Receptor Antagonists/metabolism ; Registries ; Risk Factors

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 51.

Tytuł:: Improvement of bone mineral density and markers of proximal renal tubular function in chronic hepatitis B patients switched from tenofovir disoproxil fumarate to tenofovir alafenamide.
Autorzy:: Fong TL; Asian Pacific Liver Center at Saint Vincent Medical Center, University of Southern California, Los Angeles, California.; Division of Gastrointestinal and Liver Diseases, Keck School of Medicine, University of Southern California, Los Angeles, California.
Lee BT; Division of Gastrointestinal and Liver Diseases, Keck School of Medicine, University of Southern California, Los Angeles, California.
Tien A; Asian Pacific Liver Center at Saint Vincent Medical Center, University of Southern California, Los Angeles, California.
Chang M; Asian Pacific Liver Center at Saint Vincent Medical Center, University of Southern California, Los Angeles, California.
Lim C; Asian Pacific Liver Center at Saint Vincent Medical Center, University of Southern California, Los Angeles, California.
Ahn A; Asian Pacific Liver Center at Saint Vincent Medical Center, University of Southern California, Los Angeles, California.
Bae HS; Asian Pacific Liver Center at Saint Vincent Medical Center, University of Southern California, Los Angeles, California.; Pokaż więcej
Źródło:: Journal of viral hepatitis [J Viral Hepat] 2019 May; Vol. 26 (5), pp. 561-567. Date of Electronic Publication: 2019 Jan 16.
Typ publikacji:: Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:: Bone Density*
Drug Substitution*
Adenine/*analogs & derivatives
Hepatitis B, Chronic/*complications
Hepatitis B, Chronic/*drug therapy
Kidney Diseases/*chemically induced
Phosphorous Acids/*adverse effects
Adenine/administration & dosage ; Adenine/adverse effects ; Adolescent ; Adult ; Aged ; Aged, 80 and over ; Alanine ; Female ; Glomerular Filtration Rate ; Humans ; Kidney Diseases/pathology ; Kidney Function Tests ; Male ; Middle Aged ; Pelvic Bones/pathology ; Phosphorous Acids/administration & dosage ; Prospective Studies ; Spine/pathology ; Tenofovir/analogs & derivatives ; Treatment Outcome ; Young Adult

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 52.

Tytuł:: Efficacious transition from reference infliximab to biosimilar infliximab in clinical practice.
Autorzy:: Layegh Z; Amsterdam Rheumatology and Immunology Center, Reade, Rheumatology, Amsterdam, The Netherlands.
Ruwaard J; Amsterdam Rheumatology and Immunology Center, Reade, Rheumatology, Amsterdam, The Netherlands.
Hebing RCF; Amsterdam Rheumatology and Immunology Center, Reade, Rheumatology, Amsterdam, The Netherlands.; Reade, Rheumatology, Pharmacy, Amsterdam, The Netherlands.
L' Ami MJ; Amsterdam Rheumatology and Immunology Center, Reade, Rheumatology, Amsterdam, The Netherlands.
van der Weele W; Amsterdam Rheumatology and Immunology Center, Reade, Rheumatology, Amsterdam, The Netherlands.
Nurmohamed MT; Amsterdam Rheumatology and Immunology Center, Reade, Rheumatology, Amsterdam, The Netherlands.
Krieckaert C; Amsterdam Rheumatology and Immunology Center, Reade, Rheumatology, Amsterdam, The Netherlands.
Wolbink G; Amsterdam Rheumatology and Immunology Center, Reade, Rheumatology, Amsterdam, The Netherlands.; Pokaż więcej
Źródło:: International journal of rheumatic diseases [Int J Rheum Dis] 2019 May; Vol. 22 (5), pp. 869-873. Date of Electronic Publication: 2019 Feb 14.
Typ publikacji:: Journal Article
MeSH Terms:: Drug Substitution*
Antibodies, Monoclonal/*administration & dosage
Antirheumatic Agents/*administration & dosage
Arthritis, Psoriatic/*drug therapy
Arthritis, Rheumatoid/*drug therapy
Biosimilar Pharmaceuticals/*administration & dosage
Infliximab/*administration & dosage
Aged ; Aged, 80 and over ; Antibodies, Monoclonal/adverse effects ; Antirheumatic Agents/adverse effects ; Arthritis, Psoriatic/diagnosis ; Arthritis, Psoriatic/immunology ; Arthritis, Rheumatoid/diagnosis ; Arthritis, Rheumatoid/immunology ; Biosimilar Pharmaceuticals/adverse effects ; Female ; Humans ; Infliximab/adverse effects ; Male ; Middle Aged ; Retrospective Studies ; Time Factors ; Treatment Outcome

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 53.

Tytuł:: No need to change the drug class: ixekizumab- following secukinumab-therapy in psoriasis.
Autorzy:: Bokor-Billmann T; a Department of Dermatology , Ruprecht-Karls-University Heidelberg , Heidelberg , Germany.
Schäkel K; a Department of Dermatology , Ruprecht-Karls-University Heidelberg , Heidelberg , Germany.; Pokaż więcej
Źródło:: The Journal of dermatological treatment [J Dermatolog Treat] 2019 May; Vol. 30 (3), pp. 216-220. Date of Electronic Publication: 2018 Sep 11.
Typ publikacji:: Journal Article
MeSH Terms:: Drug Substitution*
Antibodies, Monoclonal/*therapeutic use
Antibodies, Monoclonal, Humanized/*therapeutic use
Dermatologic Agents/*therapeutic use
Psoriasis/*drug therapy
Adult ; Female ; Humans ; Interleukin-17/antagonists & inhibitors ; Male ; Middle Aged ; Retrospective Studies ; Treatment Failure ; Treatment Outcome

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 54.

Tytuł:: Efficacy and Safety of Elective Switching from Intravenous to Subcutaneous Infliximab [CT-P13]: A Multicentre Cohort Study.
Autorzy:: Smith PJ; Department of Gastroenterology, Royal Liverpool Hospital, Liverpool University Hospitals NHS Foundation Trust, Liverpool, UK.
Critchley L; Department of Gastroenterology, Royal Liverpool Hospital, Liverpool University Hospitals NHS Foundation Trust, Liverpool, UK.
Storey D; Department of Gastroenterology, Royal Liverpool Hospital, Liverpool University Hospitals NHS Foundation Trust, Liverpool, UK.
Gregg B; Department of Gastroenterology, Royal Liverpool Hospital, Liverpool University Hospitals NHS Foundation Trust, Liverpool, UK.
Stenson J; Department of Gastroenterology, Royal Liverpool Hospital, Liverpool University Hospitals NHS Foundation Trust, Liverpool, UK.
Kneebone A; Department of Gastroenterology, Aintree University Hospital, Liverpool University Hospitals NHS Foundation Trust, Liverpool, UK.
Rimmer T; Department of Gastroenterology, Aintree University Hospital, Liverpool University Hospitals NHS Foundation Trust, Liverpool, UK.
Burke S; Department of Gastroenterology, Aintree University Hospital, Liverpool University Hospitals NHS Foundation Trust, Liverpool, UK.
Hussain S; Liverpool School of Medicine, University of Liverpool, Liverpool, UK.
Yi Teoh W; Liverpool School of Medicine, University of Liverpool, Liverpool, UK.
Vazeille S; Liverpool School of Medicine, University of Liverpool, Liverpool, UK.
Serna S; Department of Digestive Diseases, Kettering General Hospital, Kettering, UK.
Steel A; Department of Gastroenterology, Royal Liverpool Hospital, Liverpool University Hospitals NHS Foundation Trust, Liverpool, UK.
Derbyshire E; Department of Gastroenterology, Royal Liverpool Hospital, Liverpool University Hospitals NHS Foundation Trust, Liverpool, UK.
Collins P; Department of Gastroenterology, Royal Liverpool Hospital, Liverpool University Hospitals NHS Foundation Trust, Liverpool, UK.
Dibb M; Department of Gastroenterology, Royal Liverpool Hospital, Liverpool University Hospitals NHS Foundation Trust, Liverpool, UK.
Flanagan P; Department of Gastroenterology, Aintree University Hospital, Liverpool University Hospitals NHS Foundation Trust, Liverpool, UK.
Probert C; Department of Gastroenterology, Royal Liverpool Hospital, Liverpool University Hospitals NHS Foundation Trust, Liverpool, UK.; Molecular and Cellular Physiology, Institute of Translational Medicine, University of Liverpool, Liverpool, UK.
Verma AM; Department of Digestive Diseases, Kettering General Hospital, Kettering, UK.
Subramanian S; Department of Gastroenterology, Royal Liverpool Hospital, Liverpool University Hospitals NHS Foundation Trust, Liverpool, UK.; Department of Gastroenterology, Addenbrookes Hospital, Cambridge, UK.; Pokaż więcej
Źródło:: Journal of Crohn's & colitis [J Crohns Colitis] 2022 Sep 08; Vol. 16 (9), pp. 1436-1446.
Typ publikacji:: Journal Article; Multicenter Study
MeSH Terms:: Biosimilar Pharmaceuticals*/therapeutic use
Colitis*/chemically induced
Colitis, Ulcerative*
Crohn Disease*/diagnosis
Inflammatory Bowel Diseases*/chemically induced
Inflammatory Bowel Diseases*/drug therapy
Antibodies, Monoclonal/adverse effects ; C-Reactive Protein/metabolism ; Cohort Studies ; Drug Substitution ; Gastrointestinal Agents/therapeutic use ; Humans ; Infliximab/therapeutic use ; Leukocyte L1 Antigen Complex ; Prospective Studies ; Treatment Outcome

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 55.

Tytuł:: Factors facilitating and hindering counselling about generic substitution and a reference price system in community pharmacies - a survey among Finnish dispensers.
Autorzy:: Rainio R; School of Pharmacy, Social Pharmacy, Faculty of Health Sciences, Kuopio Campus, University of Eastern Finland, PO Box 1627, FI-70211, Kuopio, Finland. .
Ahonen R; School of Pharmacy, Social Pharmacy, Faculty of Health Sciences, Kuopio Campus, University of Eastern Finland, PO Box 1627, FI-70211, Kuopio, Finland.
Lämsä E; School of Pharmacy, Social Pharmacy, Faculty of Health Sciences, Kuopio Campus, University of Eastern Finland, PO Box 1627, FI-70211, Kuopio, Finland.
Timonen J; School of Pharmacy, Social Pharmacy, Faculty of Health Sciences, Kuopio Campus, University of Eastern Finland, PO Box 1627, FI-70211, Kuopio, Finland.; Pokaż więcej
Źródło:: BMC health services research [BMC Health Serv Res] 2022 Sep 07; Vol. 22 (1), pp. 1130. Date of Electronic Publication: 2022 Sep 07.
Typ publikacji:: Journal Article
MeSH Terms:: Pharmacies*
Counseling ; Drug Substitution ; Finland ; Humans ; Surveys and Questionnaires

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 56.

Tytuł:: A nationwide survey exploring physicians' and pharmacists' knowledge, awareness and perceptions regarding generic medicines in China.
Autorzy:: Qu J; Department of Pharmacy, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College Hospital, No.1 Shuaifuyuan Street, Beijing, Dongcheng District, China.
Zuo W; Department of Pharmacy, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College Hospital, No.1 Shuaifuyuan Street, Beijing, Dongcheng District, China.
Took RL; Department of Pharmacy Practice, St. Louis College of Pharmacy, University of Health Sciences and Pharmacy in St. Louis, St. Louis, USA.
Schafermeyer KW; Department of Pharmaceutical and Administrative Sciences, St. Louis College of Pharmacy, University of Health Sciences and Pharmacy in St. Louis, St. Louis, USA.
Lukas S; Department of Pharmaceutical and Administrative Sciences, St. Louis College of Pharmacy, University of Health Sciences and Pharmacy in St. Louis, St. Louis, USA.
Wang S; Department of Pharmacy, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College Hospital, No.1 Shuaifuyuan Street, Beijing, Dongcheng District, China.
Du L; Department of Pharmacy, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College Hospital, No.1 Shuaifuyuan Street, Beijing, Dongcheng District, China.
Liu X; Department of Pharmacy, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College Hospital, No.1 Shuaifuyuan Street, Beijing, Dongcheng District, China.
Gao Y; Department of Pharmacy, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College Hospital, No.1 Shuaifuyuan Street, Beijing, Dongcheng District, China.
Li J; Department of Pharmacy, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College Hospital, No.1 Shuaifuyuan Street, Beijing, Dongcheng District, China.
Pan H; Department of Medical Administration, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College Hospital, Beijing, China.
Du X; Department of Pharmacy, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College Hospital, No.1 Shuaifuyuan Street, Beijing, Dongcheng District, China.
Mei D; Department of Pharmacy, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College Hospital, No.1 Shuaifuyuan Street, Beijing, Dongcheng District, China.
Zhang B; Department of Pharmacy, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College Hospital, No.1 Shuaifuyuan Street, Beijing, Dongcheng District, China. .; Pokaż więcej
Źródło:: BMC health services research [BMC Health Serv Res] 2022 Aug 20; Vol. 22 (1), pp. 1069. Date of Electronic Publication: 2022 Aug 20.
Typ publikacji:: Journal Article
MeSH Terms:: Pharmacists*
Physicians*
Attitude of Health Personnel ; Cross-Sectional Studies ; Drug Substitution ; Drugs, Generic/therapeutic use ; Health Knowledge, Attitudes, Practice ; Humans ; Surveys and Questionnaires

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 57.

Tytuł:: Short interruptions of TNF-inhibitor treatment can be associated with treatment failure in patients with immune-mediated diseases.
Autorzy:: Lamberg T; United Medix Laboratories, Helsinki, Finland.; Department of Clinical Chemistry, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.
Sipponen T; Department of Gastroenterology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.
Valtanen S; United Medix Laboratories, Helsinki, Finland.; Department of Clinical Chemistry, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.
Eklund KK; Department of Rheumatology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.; Orton Orthopedic Hospital Helsinki, Helsinki, Finland.
Mälkönen T; Department of Dermatology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.
Aalto K; New Children's Hospital, Pediatric Research Center, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.
Mikola K; New Children's Hospital, Pediatric Research Center, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.
Kolho KL; Pediatric Gastroenterology, Children's Hospital, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.
Leinonen S; Tays Eye Centre, Tampere University Hospital, Tampere, Finland.
Isomäki P; Centre for Rheumatology, Tampere University Hospital, Tampere, Finland.
Mäkinen H; Centre for Rheumatology, Tampere University Hospital, Tampere, Finland.
Vidqvist KL; Centre for Rheumatology, Tampere University Hospital, Tampere, Finland.
Kokko A; Department of Rheumatology, Jyväskylä Central Hospital, Jyväskylä, Finland.
Huilaja L; PEDEGO Research Unit, University of Oulu, Oulu, Finland.; Department of Dermatology and Medical Research Center, Oulu University Hospital and University of Oulu, Oulu, Finland.
Kyllönen M; Department of Rheumatology, Oulu University Hospital, Oulu, Finland.
Keskitalo P; PEDEGO Research Unit, University of Oulu, Oulu, Finland.; Department of Pediatrics, Oulu University Hospital, Oulu, Finland.; Medical Research Center, Oulu University Hospital and University of Oulu, Oulu, Finland.
Sard S; PEDEGO Research Unit, University of Oulu, Oulu, Finland.; Department of Pediatrics, Oulu University Hospital, Oulu, Finland.; Medical Research Center, Oulu University Hospital and University of Oulu, Oulu, Finland.
Vähäsalo P; PEDEGO Research Unit, University of Oulu, Oulu, Finland.; Department of Pediatrics, Oulu University Hospital, Oulu, Finland.; Medical Research Center, Oulu University Hospital and University of Oulu, Oulu, Finland.
Koskela R; Department of Gastroenterology, Oulu University Hospital, Oulu, Finland.
Kröger L; Department of Pediatrics, Kuopio University Hospital, Kuopio, Finland.
Lahtinen P; Department of Gastroenterology, Päijät-Häme Central Hospital, Lahti, Finland.
Haapala AM; Department of Clinical Microbiology, Fimlab Laboratories, Tampere, Finland.
Korkatti K; Department of Pediatrics, Central Ostrobothnia Central Hospital, Kokkola, Finland.
Sokka-Isler T; Department of Rheumatology, Jyväskylä Central Hospital, Jyväskylä, Finland.
Jokiranta TS; United Medix Laboratories, Helsinki, Finland.; Medicum, University of Helsinki, Helsinki, Finland.; Tammer BioLab Ltd, Tampere, Finland.; Pokaż więcej
Corporate Authors:: BLING Research Group
Źródło:: Autoimmunity [Autoimmunity] 2022 Aug; Vol. 55 (5), pp. 275-284. Date of Electronic Publication: 2022 Apr 28.
Typ publikacji:: Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:: Rheumatic Diseases*/drug therapy
Tumor Necrosis Factor Inhibitors*/therapeutic use
Adalimumab/therapeutic use ; Case-Control Studies ; Drug Substitution ; Finland ; Humans ; Infliximab/therapeutic use ; Retrospective Studies ; Treatment Failure

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 58.

Tytuł:: Efficacy and improvement of lipid profile after switching to rilpivirine in resource limited setting: real life clinical practice.
Autorzy:: Gatechompol S; HIV-NAT, Thai Red Cross AIDS Research Centre, 104 Ratchadamri Road, Pathumwan, Bangkok, 10330, Thailand. .; Faculty of Medicine, Chulalongkorn University and King Chulalongkorn Memorial Hospital, Thai Red Cross Society, Rama 4 Road, Pathumwan, Bangkok, 10330, Thailand. .
Avihingsanon A; HIV-NAT, Thai Red Cross AIDS Research Centre, 104 Ratchadamri Road, Pathumwan, Bangkok, 10330, Thailand.; Faculty of Medicine, Chulalongkorn University and King Chulalongkorn Memorial Hospital, Thai Red Cross Society, Rama 4 Road, Pathumwan, Bangkok, 10330, Thailand.
Apornpong T; HIV-NAT, Thai Red Cross AIDS Research Centre, 104 Ratchadamri Road, Pathumwan, Bangkok, 10330, Thailand.
Han WM; HIV-NAT, Thai Red Cross AIDS Research Centre, 104 Ratchadamri Road, Pathumwan, Bangkok, 10330, Thailand.
Kerr SJ; HIV-NAT, Thai Red Cross AIDS Research Centre, 104 Ratchadamri Road, Pathumwan, Bangkok, 10330, Thailand.; Faculty of Medicine, Chulalongkorn University and King Chulalongkorn Memorial Hospital, Thai Red Cross Society, Rama 4 Road, Pathumwan, Bangkok, 10330, Thailand.
Ruxrungtham K; HIV-NAT, Thai Red Cross AIDS Research Centre, 104 Ratchadamri Road, Pathumwan, Bangkok, 10330, Thailand.; Faculty of Medicine, Chulalongkorn University and King Chulalongkorn Memorial Hospital, Thai Red Cross Society, Rama 4 Road, Pathumwan, Bangkok, 10330, Thailand.; Pokaż więcej
Źródło:: AIDS research and therapy [AIDS Res Ther] 2019 Apr 05; Vol. 16 (1), pp. 7. Date of Electronic Publication: 2019 Apr 05.
Typ publikacji:: Journal Article
MeSH Terms:: Drug Substitution*
Anti-HIV Agents/*therapeutic use
HIV Infections/*drug therapy
Lipids/*blood
Rilpivirine/*therapeutic use
Adult ; Antiretroviral Therapy, Highly Active ; Female ; HIV-1/drug effects ; Health Resources ; Humans ; Male ; Middle Aged ; Prospective Studies ; RNA, Viral/blood ; Reverse Transcriptase Inhibitors/therapeutic use ; Treatment Failure ; Viral Load/drug effects

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 59.

Tytuł:: Evaluating the effects of switching from dutasteride to tadalafil in benign prostatic hyperplasia patients with lower urinary tract symptoms: A randomized, open-label, multicenter study.
Autorzy:: Matsumoto T; Department of Urology, Hirosaki University Graduate School of Medicine, Hirosaki, Japan.
Hatakeyama S; Department of Urology, Hirosaki University Graduate School of Medicine, Hirosaki, Japan.
Narita T; Department of Urology, Hirosaki University Graduate School of Medicine, Hirosaki, Japan.
Yoneyama T; Department of Urology, Hirosaki University Graduate School of Medicine, Hirosaki, Japan.
Hashimoto Y; Department of Urology, Hirosaki University Graduate School of Medicine, Hirosaki, Japan.
Ohyama C; Department of Urology, Hirosaki University Graduate School of Medicine, Hirosaki, Japan.; Pokaż więcej
Źródło:: International journal of urology : official journal of the Japanese Urological Association [Int J Urol] 2019 Apr; Vol. 26 (4), pp. 522-523. Date of Electronic Publication: 2019 Jan 18.
Typ publikacji:: Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
MeSH Terms:: Drug Substitution*
Dutasteride/*administration & dosage
Lower Urinary Tract Symptoms/*drug therapy
Prostatic Hyperplasia/*drug therapy
Sexual Dysfunction, Physiological/*diagnosis
Tadalafil/*administration & dosage
5-alpha Reductase Inhibitors/administration & dosage ; 5-alpha Reductase Inhibitors/adverse effects ; Aged ; Dose-Response Relationship, Drug ; Dutasteride/adverse effects ; Humans ; Lower Urinary Tract Symptoms/etiology ; Male ; Patient Satisfaction/statistics & numerical data ; Phosphodiesterase 5 Inhibitors/administration & dosage ; Phosphodiesterase 5 Inhibitors/adverse effects ; Prostatic Hyperplasia/complications ; Severity of Illness Index ; Sexual Dysfunction, Physiological/drug therapy ; Sexual Dysfunction, Physiological/etiology ; Tadalafil/adverse effects ; Treatment Outcome

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 60.

Tytuł:: Two-drug vs. three-drug combinations for HIV-1: Do we have enough data to make the switch?
Autorzy:: Moreno S; Department of Infectious Diseases, University Hospital Ramón y Cajal, Alcalá University, IRYCIS, Madrid, Spain.
Perno CF; Department of Laboratory Medicine, ASST Niguarda Hospital, University of Milan, Milan, Italy.
Mallon PW; HIV Molecular Research Group, School of Medicine, University College Dublin, Dublin, Ireland.
Behrens G; Department for Rheumatology and Clinical Immunology, Hannover Medical School, Hannover, Germany.
Corbeau P; Institute for Human Genetics, CNRS-Montpellier University UMR9002, Montpellier, France.; Immunology Department, University Hospital, Nîmes, France.
Routy JP; Division of Hematology and Chronic Viral Infection Service, McGill University Health Centre, Montréal, QC, Canada.
Darcis G; Department of Infectious Diseases, Liege University Hospital, University of Liege, Liège, Belgium.; Pokaż więcej
Źródło:: HIV medicine [HIV Med] 2019 Apr; Vol. 20 Suppl 4, pp. 2-12.
Typ publikacji:: Journal Article; Review
MeSH Terms:: Drug Substitution*
Anti-Retroviral Agents/*therapeutic use
Antiretroviral Therapy, Highly Active/*methods
HIV Infections/*drug therapy
CD4 Lymphocyte Count ; Drug-Related Side Effects and Adverse Reactions/epidemiology ; Humans ; Sustained Virologic Response

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Informacja

Wyszukujesz frazę ""Drug Substitution"" wg kryterium: Temat

Źródło danych

Ogranicz do:

Ogranicz do bazy

Typ dokumentu

Temat

Wydawca

Publikacja

Język

Rok publikacji